Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: FSGS
Interventions: APL2, Placebo; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Vitamin A Status
Interventions: b-carotene, retinyl palmitate, placebo; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Davis, California

Conditions: Constipation, Chronic Idiopathic Constipation, CIC
Interventions: BLI400 Laxative, BLI400 Placebo; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 51
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more

Conditions: Asthma
Interventions: Lansoprazole, Matching placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more

Conditions: Dyspepsia, Helicobacter Pylori Infection
Interventions: RHB-105, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Anaheim, California • Chino, California • Jupiter, Florida + 8 more

Conditions: Alcohol Use Disorder, Insomnia
Interventions: Daridorexant, Placebo, Brief Counseling, MEMS and Medication Accounting, Contingency Management for Medication Adherence; Drug · Behavioral · Device
Lead sponsor: Sterling McPherson; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Premature Birth
Interventions: Betamethasone - ACTIVE, Normal Saline - PLACEBO; Drug · Other
Lead sponsor: Pediatrix; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 6 more

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 27
States / cities: Goodyear, Arizona • Peoria, Arizona • Huntington Beach, California + 22 more

Conditions: Myasthenia Gravis
Interventions: IGIV-C, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Orange, California • New Haven, Connecticut • Jacksonville, Florida + 11 more

Conditions: Lupus Nephritis
Interventions: Atacicept, Mycophenolate mofetil, Placebo, Corticosteroids; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 9 more

Conditions: Central Abdominal Bulging
Interventions: LIPO-202, Placebo; Drug
Lead sponsor: Neothetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 6
States / cities: Encinitas, California • Manhattan Beach, California • Aventura, Florida + 3 more

Conditions: Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc, Spinal Diseases
Interventions: Dexmedetomidine, 0.9% Saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder
Interventions: THC-dominant cannabis, CBD-dominant cannabis, Cannabis placebo, Alcohol, Alcohol placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Asthma
Interventions: Omalizumab, Placebo, Fluticasone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 56
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more

Conditions: Alcohol Abuse
Interventions: Protandim; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more

Conditions: Headache
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Surgical Abortion, Patient Satisfaction, Anesthesia, Pain
Interventions: Placebo oil, Lavender oil.; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hypertension
Interventions: clevidipine, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Hudson, Florida + 7 more

Conditions: Chronic Low Back Pain, Degenerative Disc Disease, Depression, Anxiety
Interventions: Oxycodone, Morphine, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Moderate to Severe Glabellar Frown Lines
Interventions: IncobotulinumtoxinA (Xeomin) (20 Units), Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more

Conditions: Colorectal Cancer, Coffee, Gastrointestinal Microbiome, Stenosis, Fibrosis, Liver, Ultrasound Elastography, Proton Magnetic Resonance Spectroscopy
Interventions: Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule., Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: E-Aminocaproic Acid, Bilateral Varus Rotational Osteotomy
Interventions: E-Aminocaproic acid; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 1 Year to 18 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions: Pegcetacoplan, Placebo; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 20 more

Search by objective public record fields.

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

Effect of Small Daily Doses of B-carotene on Breast Milk Retinol

BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Lansoprazole to Treat Children With Asthma

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

Daridorexant for People With Insomnia and Alcohol Use Disorder Study

Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion

Cannabis' Impact on Alcohol Consumption

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

Antioxidant Replacement Therapy in Patients With Alcohol Abuse

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Ketamine for Acute Migraine in the Emergency Department

Effects of Aromatherapy on Patient Satisfaction With Surgical Abortion at Less Than 10 Weeks Gestation

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis